Adherence to antiretroviral therapy among HIV-infected drug users: A meta-analysis

AIDS and Behavior

Volumn 14, Issue 4, 2010, Pages 731-747

  Malta, Monica ^a   Magnanini, Monica M F ^b   Strathdee, Steffanie A ^c   Bastos, Francisco I ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adherence; AIDS; Drug use; HIV; Meta analysis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; DRUG USE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; META ANALYSIS; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; STATISTICS; TREATMENT OUTCOME; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG USERS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; TREATMENT OUTCOME;

EID: 77956883522     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-008-9489-7     Document Type: Article

References (98)

1. Aceijas, C., Oppenheimer, E., Stimson, G. V., Ashcroft, R. E., Matic, S., & Hickman, M. (2006). Antiretroviral treatment for injecting DU in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5"). Addiction (Abingdon, England), 101, 1246-1253. doi:10.1111/j.1360-0443.2006.01509.x. (Pubitemid 44199515)
2. Altice, F. L., Mezger, J. A., Hodges, J., Bruce, R. D., Marinovich, A., Walton, M., et al. (2004). Developing a directly administered antiretroviral therapy intervention for HIV-infected DU: Implications for program replication. Clinical Infectious Diseases, 38, S376-S387. doi:10.1086/421400. (Pubitemid 38738534)
3. Altice, F. L., Mostashari, F., & Friedland, G. H. (2001). Trust and the acceptance of and adherence to antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 28, 47-58.
4. Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., et al. (2001). The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Annals of Internal Medicine, 134, 663-694. (Pubitemid 32322245)
5. Arnsten, J. H., Demas, P. A., Farzadegan, H., Grant, R. W., Gourevitch, M. N., Chang, C. J., et al. (2001). Antiretroviral therapy adherence and viral suppression in HIV-infected DU: Comparison of self-report and electronic monitoring. Clinical Infectious Diseases, 33, 1417-1423. doi:10.1086/323201. (Pubitemid 32955198)
6. Arnsten, J. H., Li, X., Mizuno, Y., Knowlton, A. R., Gourevitch, M. N., Handley, K., et al. (2007). Factors associated with antiret-roviral therapy adherence and medication errors among HIV-infected injection drug users. Journal of Acquired Immune Deficiency Syndromes, 46, S64-S71.
7. Atkinson, J. S., Schönnesson, L. N., Williams, M. L., & Timpson, S. C. (2008). Associations among correlates of schedule adherence to antiretroviral therapy (ART): A path analysis of a sample of crack cocaine using sexually active African-Americans with HIV infection. AIDS Care, 20, 253-262. doi:10.1080/095401207015 06788. (Pubitemid 351651273)
8. Avants, S. K., Margolin, A., Warburton, L. A., Hawkins, K. A., & Shi, J. (2001). Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. The American Journal on Addictions, 10, 69-78. doi:10.1080/105504901 750160501. (Pubitemid 32201734)
9. Bangsberg, D. R. (2006). Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clinical Infectious Diseases, 43, 939-941. doi:10.1086/ 507526. (Pubitemid 44435526)
10. Bassetti, S., Battegay, M., Furrer, H., Rickenbach, M., Flepp, M., Kaiser, L., et al. (1999). Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV cohort study. Journal of Acquired Immune Deficiency Syndromes, 21, 114-119.
11. Berlin, J. A. (1995). Invited commentary. American Journal of Epidemiology, 142, 383-387.
12. Bouhnik, A. D., Chesney, M., Carrieri, P., Gallais, H., Moreau, J., Moatti, J. P., et al. (2002). Nonadherence among HIV-infected injecting DU: The impact of social instability. Journal of Acquired Immune Deficiency Syndromes, 31, S149-S153.
13. Bouhnik, A. D., Preau, M., Vincent, E., Carrieri, M. P., Gallais, H., Lepeu, G., et al. (2005). Depression and clinical progression in HIV-infected DU treated with highly active antiretroviral therapy. Antiviral Therapy, 10, 53-61.
14. Carrieri, M. P., Chesney, M. A., Spire, B., Loundou, A., Sobel, A., Lepeu, G., et al. (2003a). Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting DU. International Journal of Behavioral Medicine, 10, 1-14. doi:10.1207/S15327558IJBM1001-01.
15. Carrieri, M. P., Raffi, F., Lewden, C., Sobel, A., Michelet, C., Cailleton, V., et al. (2003b). Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: A 3-year follow-up study. Antiviral Therapy, 8, 585-594.
16. Celentano, D. D., Galai, N., Sethi, A. K., Shah, N. G., Strathdee, S. A., Vlahov, D., et al. (2001). Time to initiating highly active antiretroviral therapy among HIV-infected injection DU. AIDS (London, England), 15, 1707-1715. (Pubitemid 32918126)
17. Celentano, D. D., Vlahov, D., Cohn, S., Shadle, V. M., Obasanjo, O., & Moore, R. D. (1998). Self-reported antiretroviral therapy in injection DU. JAMA: The Journal of the American Medical Association, 280, 544-546. doi:10.1001/jama.280.6.544. (Pubitemid 28377674)
18. Chesney, M. A. (2006). The Elusive Gold Standard: Future Perspectives for HIV Adherence Assessment and Intervention. Journal of Acquired Immune Deficiency Syndromes, 43, S149-S155. doi:10.1097/01.qai.0000243112.91293.26. (Pubitemid 44885655)
19. Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwickl, B., et al. (2000). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care, 12, 255-266.
20. Clarke, S., Delamere, S., McCullough, L., Hopkins, S., Bergin, C., & Mulcahy, F. (2003). Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting DU. HIV Medicine, 4, 33-37. doi:10.1046/j.1468-1293.2003.00130.x. (Pubitemid 37161534)
21. Cofrancesco, J., Jr., Scherzer, R., Tien, P. C., Gibert, C. L., Southwell, H., Sidney, S., et al. (2008). Illicit drug use and HIV treatment outcomes in a US cohort. AIDS (London, England), 22, 357-365.
22. Cooper, H., & Hedges, L. V. (1994). The handbook of research synthesis. New York: Russell Sage Foundation.
23. Crisp, B. R., Williams, M., Timpson, S., & Ross, M. W. (2004). Medication compliance and satisfaction with treatment for HIV disease in a sample of African-American crack cocaine smokers. AIDS and Behavior, 8, 199-206. doi:10.1023/B:AIBE.0000030 250.33931.af.
24. Crystal, S., Sambamoorthi, U., Moynihan, P. J., & McSpiritt, E. (2001). Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS. Journal of General Internal Medicine, 16, 850-859. doi:10.1046/j.1525-1497.2001.01025.x. (Pubitemid 34015701)
25. DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7, 177-188. doi:10.1016/0197-2456 (86)90046-2.
26. Des Jarlais, D. C., Lyles, C., & Crepaz, N. (2004). Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: The TREND statement. American Journal of Public Health, 94, 361-366.
27. Duran, S., Solas, C., Spire, B., Carrieri, M. P., Fuzibet, J. G., Costagliola, D., et al. (2001). Do HIV-infected injecting DU over-report adherence to highly active antiretroviral therapy? A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. AIDS (London, England), 15, 1075-1077. doi:10.1097/000020 30-200105250-00024.
28. Egger, M., May, M., Chene, G., Phillips, A. N., Ledergerber, B., Dabis, F., et al. (2002). Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet, 360, 119-129. doi: 10.1016/S0140-6736(02)09411-4. (Pubitemid 34786200)
29. Escobar, I., Campo, M., Martin, J., Fernandez-Shaw, C., Pulido, F., & Rubio, R. (2003). Factors affecting patient adherence to highly active antiretroviral therapy. The Annals of Pharmacotherapy, 37, 775-781. doi:10.1345/aph.1C427. (Pubitemid 36618359)
30. Fleiss, J. L. (1993). The statistical basis of meta-analysis. Statistical Methods in Medical Research, 2, 121-145. doi:10.1177/0962280 29300200202.
31. Friedland, G., & Williams, A. (1999). Attaining higher goals in HIV treatment: The central importance of adherence. AIDS (London, England), 13(Suppl 1), S61-S72.
32. Gordillo, V., del Amo, J., Soriano, V., & Gonzalez-Lahoz, J. (1999). Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS (London, England), 13, 1763-1769. doi:10.1097/00002030-199909100-00021. (Pubitemid 30015725)
33. Haug, N. A., Sorensen, J. L., Lollo, N. D., Gruber, V. A., Delucchi, K. L., & Hall, S. M. (2005). Gender differences among HIV-positive methadone maintenance patients enrolled in a medication adherence trial. AIDS Care, 17, 1022-1029. doi:10.1080/ 09540120500100882. (Pubitemid 41499315)
34. Hedges, L. V., & Vevea, J. L. (1998). Fixed and random effects models in meta-analysis. Psychological Methods, 3, 486-504. doi:10.1037/1082-989X.3.4. 486.
35. Higgins, J. P., & Thompson, S. G. (2002). Quantifying heterogeneity in a meta-analysis. Statistics in Medicine, 21, 1539-1558. doi:10.1002/sim.1186. (Pubitemid 34746062)
36. Higgins, J. P., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed.), 327, 557-560. doi:10.1136/bmj.327.7414.557.
37. Hinkin, C. H., Barclay, T. R., Castellon, S. A., Levine, A. J., Durvasula, R. S., Marion, S. D., et al. (2007). Drug use and medication adherence among HIV-1 infected individuals. AIDS and Behavior, 11, 185-194. doi:10.1007/s10461-006-9152-0.
38. Hogg, R. S., Heath, K. V., Yip, B., Craib, K. J., O'Shaughnessy, M. V., Schechter, M. T., et al. (1998). Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA: The Journal of the American Medical Association, 279, 450-454. doi:10.1001/jama.279.6.450. (Pubitemid 28082255)
39. Howard, A. A., Arnsten, J. H., Vlahov, D., Rich, J. D., Schuman, P., Stone, V. E., et al. (2002). A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS (London, England), 16, 2175-2182. doi:10.1097/000020 30-200211080-00010.
40. Huedo-Medina, T. B., Sánchez-Meca, J., Marín- Martínez, F., & Botella, J. (2006). Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychological Methods, 11, 193-206. doi:10.1037/1082-989X.11.2.193. (Pubitemid 44001277)
41. Inciardi, J. A., & Surratt, H. L. (2001). Cross-cultural approaches to harm reduction research: Some considerations on the Brazil experience. Substance Use & Misuse, 36, 201-212.
42. Kerr, T., Marshall, A., Walsh, J., Palepu, A., Tyndall, M., Montaner, J., et al. (2005). Determinants of HAART discontinuation among injection drug users. AIDS Care, 17, 539-549. (Pubitemid 40979462)
43. Kerr, T., Palepu, A., Barness, G., Walsh, J., Hogg, R., Montaner, J., et al. (2004). Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver. Antiviral Therapy, 9, 407-414. (Pubitemid 38878756)
44. Knowlton, A., Arnsten, J., Eldred, L., Wilkinson, J., Gourevitch, M., Shade, S., et al. (2006). Individual, interpersonal, and structural correlates of effective HAART use among urban active injection DU. Journal of Acquired Immune Deficiency Syndromes, 41, 486-492. doi:10.1097/01.qai.0000186392.26334. e3.
45. Latkin, C. A., Knowlton, A. R., Sherman, S. (2001). Routes of drug administration, differential affiliation, and lifestyle stability among cocaine and opiate users: Implications to HIV prevention. Journal of Substance Abuse, 13, 89-102.
46. Lipsey, M. W., & Wilson, D. B. (2001). Practical meta-analysis. Thousand Oaks: Sage.
47. Liu, H., Longshore, D., Williams, J. K., Rivkin, I., Loeb, T., Warda, U. S., et al. (2006). Substance abuse and medication adherence among HIV-positive women with histories of child sexual abuse. AIDS and Behavior, 10, 279-286. doi:10.1007/s10461-005-9041-y.
48. Lu, M., Safren, S. A., Skolnik, P. R., Rogers, W. H., Coady, W., Hardy, H., et al. (2008). Optimal recall period and response task for self-reported HIV medication adherence. AIDS and Behavior, 12, 86-94. doi:10.1007/s10461-007- 9261-4. (Pubitemid 351143454)
49. Lucas, G. M., Cheever, L. W., Chaisson, R. E., & Moore, R. D. (2001). Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes, 27, 251-259.
50. Lucas, G. M., Gebo, K. A., Chaisson, R. E., & Moore, R. D. (2002). Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS (London, England), 16, 767-774. doi:10.1097/00002030-200203290-00 012. (Pubitemid 34274467)
51. Malta, M., Strathdee, S.A., Magnanini, M. M. F., & Bastos, F.I. (2008). Adherence to antiretroviral therapy for HIV/AIDS among drug users-a systematic review. Addiction (Abingdon, England), 103, 1242-1257. doi:10.1111/j.1360-0443.2008.02269.x. (Pubitemid 352009054)
52. Martin, L. L., Hermandez, S. O., & Carrobles, J. A. (2005). Psychosocial variables in the antiretroviral treatment adherence in methadone maintenance patients [Article in Spanish]. Psicot-hema, 17, 575-581.
53. Martini, M., Recchia, E., Nasta, P., Castanotto, D., Chiaffarino, F., Parazzini, F., et al. (2004). Illicit drug use: Can it predict adherence to antiretroviral therapy? European Journal of Epidemiology, 19, 585-587. doi:10.1023/B:EJEP.0000032353. 03967.ef.
54. Martín-Sánchez, V., Ortega-Vaĺin, L., Pérez-Simón Mdel, R., Most-aza-Fernández, J. L., Ortiz de Urbina-González, J. J., Rodŕiguez-María, M., et al. (2002). Factors predicting lack of adherence to highly active antiretroviral treatment. Enfermedades Infecciosas y Microbiología Clínica, 20, 491-497. [Article in Spanish].
55. Mathers, B. M., Degenhardt, L., Phillips, B., Wiessing, L., Hickman, M., Strathdee, S. A., et al. (2008). Global epidemiology of injecting drug use and HIV among people who inject drugs: A systematic review. The Lancet, 372(9651), 1733-1745. doi:10.1016/S0140-6736(08)61311-2.
56. McNabb, J., Ross, J. W., Abriola, K., Turley, C., Nightingale, C. H., & Nicolau, D. P. (2001). Adherence to highly active antiretro-viral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clinical Infectious Diseases, 33, 700-705. doi:10.1086/322590. (Pubitemid 32762944)
57. Miller, M. F., Haley, C., Koziel, M. J., & Rowley, C. F. (2005). Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: A meta-analysis. Clinical Infectious Diseases, 41, 713-720. doi:10.1086/432618. (Pubitemid 41170361)
58. Mills, E. J., Nachega, J. B., Buchan, I., Orbinski, J., Attaran, A., Singh, S., et al. (2006). Adherence to antiretroviral therapy in sub-Saharan Africa and North America: A meta-analysis. JAMA: The Journal of the American Medical Association, 296, 679-690. doi:10.1001/jama.296.6.679. (Pubitemid 44200639)
59. Moatti, J. P., Carrieri, M. P., Spire, B., Gastaut, J. A., Cassuto, J. P., & Moreau, J. (2000). Adherence to HAART in French HIV-infected injecting DU: The contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS (London, England), 14, 151-155. doi:10.1097/00002030- 200001280-00010. (Pubitemid 30116440)
60. Moher, D., Coo, D. J., Eastwood, S., Olin, I., Rennie, D., & Stroup, D. F. (2000). Improving the quality of reports of meta-analysis of randomized controlled trials: The QUOROM Statement. British Journal of Surgery, 87, 1448-1454. doi:10.1046/j.1365-2168.2000.01610.x.
61. Moher, D., Schulz, K. F., & Altman, D. G. (2001). The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet, 357, 1191-1194. doi:10.1016/S0140- 6736(00)04337-3. (Pubitemid 32378696)
62. New York State Department of Health. (2005). Adherence to antiretroviral therapy among substance users. New York (NY): New York State Department of Health.
63. Palella, F. J., Jr, Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. The New England Journal of Medicine, 338, 853-860. doi:10.1056/ NEJM199803263381301.
64. Palepu, A., Horton, N. J., Tibbetts, N., Meli, S., & Samet, J. H. (2004a). Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: The impact of substance abuse treatment. Addiction (Abingdon, England), 99, 361-368. doi:10.1111/j.1360-0443.2003.00670.x. (Pubitemid 38333828)
65. Palepu, A., Tyndall, M. W., Chan, K., Wood, E., Montaner, J. S., & Hogg, R. S. (2004b). Initiating highly active antiretroviral therapy and continuity of HIV care: The impact of incarceration and prison release on adherence and HIV treatment outcomes. Antiviral Therapy, 9, 713-719.
66. Palepu, A., Tyndall, M. W., Joy, R., Kerr, T., Wood, E., Press, N., et al. (2006). Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection DU: The role of methadone maintenance therapy. Drug and Alcohol Dependence, 84, 188-194. doi:10.1016/j.drugalcdep.2006.02.003. (Pubitemid 44119095)
67. Palepu, A., Tyndall, M. W., Li, K., Yip, B., O'Shaughnessy, M. V., Schechter, M. T., et al. (2003a). Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection DU starting antiretroviral therapy. Journal of Urban Health, 80, 667-675. doi:10.1093/jurban/jtg073. (Pubitemid 38146230)
68. Palepu, A., Tyndall, M., Yip, B., O'Shaughnessy, M. V., Hogg, R. S., & Montaner, J. S. (2003b). Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. Journal of Acquired Immune Deficiency Syndromes, 32, 522-526. doi:10.1097/00126334- 200304150-00009. (Pubitemid 36423124)
69. Parruti, G., Manzoli, L., Toro, P. M., D'Amico, G., Rotolo, S., Graziani, V., et al. (2006). Long-term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: Predictors and impact on virologic response and relapse. AIDS Patient Care and STDs, 20, 48-56
70. Pearson, C. R., Micek, M. A., Simoni, J. M., Hoff, P. D., Matediana, E., Martin, D. P., et al. (2007a). Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. Journal of Acquired Immune Deficiency Syndromes, 46, 238-244. doi:10.1097/QAI.0b013e318153f7ba. (Pubitemid 47482621)
71. Pearson C. R., Simoni, J. M., Hoff, P., Kurth, A. E., & Martin, D. P. (2007b). Assessing antiretroviral adherence via electronic drug monitoring and self-report: An examination of key methodological issues. AIDS and Behavior. 11, 161-173. doi:10.1007/ s10461-006-9133-3.
72. Pinheiro, C., De-Carvalho-Leite, J., Drachler, M., & Silveira, V. L. (2002). Factors associated with adherence to antiretroviral therapy in HIV/AIDS patients: A cross-sectional study in southern Brazil. Brazilian Journal of Medical and Biological Research, 35, 1173-1181.
73. Pradier, C., Carrieri, P., Bentz, L., Spire, B., Dellamonica, P., Moreau, J., et al. (2001). Impact of short-term adherence on virological and immunological success of HAART: A case study among French HIV-infected IDU. International Journal of STD and AIDS, 12, 324-328. doi:10.1258/ 0956462011923165. (Pubitemid 32453139)
74. Purcell, D. W., Metsch, L. R., Latka, M., Santibanez, S., Gomez, C. A., Eldred, L., et al. (2004). Interventions for seropositive injectors-research and evaluation: An integrated behavioral intervention with HIV-positive injection DU to address medical care, adherence, and risk reduction. Journal of Acquired Immune Deficiency Syndromes, 37, S110-S118. doi:10.1097/01.qai.0000 140609.44016.c4.
75. Quinn, T. C., Wawer, M. J., Sewankambo, N., Serwadda, D., Li, C., Wabwire-Mangen, F., et al. (2000). Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. The New England Journal of Medicine, 342, 921-929. doi:10.1056/NEJM200003303421303. (Pubitemid 30177052)
76. R Core Development Core Team. (2004). R: A language and environment for statistical computing. Vienna, Austria: R-Foun-dation for Statistical Computing. Retrieved June 18, 2008, from: http://www.R-project.org.
77. Roca, B., Gomez, C. J., & Arnedo, A. (1999). Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: Adherence, side effects and efficacy. The Journal of Infection, 39, 141-145. doi:10.1016/S0163-4453(99) 90006-3.
78. Sharpe, T. T., Lee, L. M., Nakashima, A. K., Elam-Evans, L. D., & Fleming, P. L. (2004). Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. Journal of Community Health, 29, 117-127. doi:10.1023/ B:JOHE.0000016716.99847.9b.
79. Simoni, J. M., Pantalone, D. W., Plummer, M. D., & Huang, B. (2007). A randomized controlled trial of a peer support intervention targeting antiretroviral medication adherence and depressive symptomatology in HIV-positive men and women. Health Psychology, 26, 488-495. doi:10.1037/0278- 6133.26.4.488. (Pubitemid 47445006)
80. Smith-Rohrberg, D., Mezger, J., Walton, M., Bruce, R. D., & Altice, F. L. (2006). Impact of Enhanced Services on Virologic Outcomes in a Directly Administered Antiretroviral Therapy Trial for HIV-Infected DU. Journal of Acquired Immune Deficiency Syndromes, 43, S48-S53. doi:10.1097/01.qai.0000 248338.74943.85.
81. Strathdee, S. A., Palepu, A., Cornelisse, P. G., Yip, B., O'Shaugh-nessy, M. V., Montaner, J. S., et al. (1998). Barriers to use of free antiretroviral therapy in injection drug users. JAMA: The Journal of the American Medical Association, 280, 547-549. doi:10.1001/jama.280.6.547. (Pubitemid 28377675)
82. Stroup, D. F., Berlin, J. A., Morton, S. C., Olkin, I., Williamson, G. D., Rennie, D., et al. (2000). Meta-analysis of observational studies in epidemiology: A proposal for reporting. JAMA: The Journal of the American Medical Association, 283, 2008-2012. doi:10.1001/jama.283.15.2008.
83. Turner, B. J., Laine, C., Cosler, L., & Hauck, W. W. (2003). Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected DU. Journal of General Internal Medicine, 18, 248-257. doi:10.1046/j.1525-1497.2003. 20122.x.
84. van Houwelingen, H. C., Arends, L. R., & Stijnen, T. H. (2002). Tutorial in biostatistics. Advanced methods in meta-analysis: Multivariate approach and meta-regression. Statistics in Medicine, 21, 589-624. doi:10.1002/sim.1040. (Pubitemid 34141379)
85. Viechtbauer, W. (2007). MiMa: An S-Plus/R function to fit meta-analytic mixed-, random-, and fixed-effects models. http:// www.wvbauer.com/downloads/ mima.ssc. Retrieved 18 June 2008.
86. Vissoci Reiche, E. M., Bonametti, A. M., Morimoto, H. K., Morimoto, A. A., Wiechemann, S. L., Matsuo, T., et al. (2008). Epidemiological, immunological and virological characteristics, and disease progression of HIV-1/HCV-co-infectedc patients from a southern Brazilian population. International Journal of Molecular Medicine, 21, 387-395.
87. Vlahov, D., & Celentano, D. D. (2006). Access to highly active antiretroviral therapy for injection DU: Adherence, resistance, and death. Cadernos de Saude Publica, 22, 705-718.
88. Wainberg, M. A., & Friedland, G. (1998). Public health implications of antiretroviral therapy and HIV drug resistance. JAMA: The Journal of the American Medical Association, 279, 1977-1983.
89. Waldrop-Valverde, D., Ownby, R. L., Wilkie, F. L., Mack, A., Kumar, M., & Metsch, L. (2006). Neurocognitive aspects of medication adherence in HIV-positive injecting DU. AIDS and Behavior, 10, 287-297. doi:10.1007/s10461- 005-9062-6.
90. Waldrop-Valverde, D., & Valverde, E. (2005). Homelessness and psychological distress as contributors to antiretroviral nonadher-ence in HIV-positive injecting DU. AIDS Patient Care and STDs, 19, 326-334. doi:10.1089/apc.2005.19.326. (Pubitemid 40770656)
91. Wang, C., Vlahov, D., Galai, N., Bareta, J., Strathdee, S. A., Nelson, K. E., et al. (2004). Mortality in HIV-seropositive versus seronegative persons in the era of highly active antiretroviral therapy: Implications for when to initiate therapy. The Journal of Infectious Diseases, 190, 1046-1054. doi:10.1086/422848. (Pubitemid 39186789)
92. Wensing, A. M., van de Vijver, D. A., Angarano, G., Asjö, B., Balotta, C., Boeri, E., et al. (2005). Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. The Journal of Infectious Diseases, 192, 958-966.
93. WHO/UNAIDS. (2007). Report on the global AIDS epidemic. Genebra: UNAIDS and WHO, 2007.
94. Wood, E., Hogg, R. S., Lima, V. D., Kerr, T., Yip, B., Marshall, B. D., et al. (2008). Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA: The Journal of the American Medical Association, 300, 550-554. doi:10.1001/ jama.300.5.550.
95. Wood, E., Hogg, R. S., Yip, B., Harrigan, P. R., O'Shaughnessy, M. V., & Montaner, J. S. (2004a). The impact of adherence on CD4 cell count responses among HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes, 35, 261-268. doi:10.1097/00126334-200403010-00006. (Pubitemid 38280651)
96. Wood, E., Montaner, J. S., Bangsberg, D. R., Tyndall, M. W., Strathdee, S. A., O'Shaughnessy, M. V., et al. (2003a). Expanding access to HIV antiretroviral therapy to marginalised populations in the developed world. AIDS (London, England), 17, 2419-2427. doi:10.1097/00002030-200311210-00003. (Pubitemid 38393313)
97. Wood, E., Montaner, J. S., Yip, B., Tyndall, M. W., Schechter, M. T., O'Shaughnessy, M. V., et al. (2003b). Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection DU. Canadian Medical Association Journal, 169, 656-661.
98. Wood, E., Montaner, J. S., Yip, B., Tyndall, M. W., Schechter, M. T., O'Shaughnessy, M. V., et al. (2004b). Adherence to antiretro-viral therapy and CD4 T-cell count responses among HIV-infected injection drug users. Antiviral Therapy, 9, 229-235.